

# Nucleo CMP<sup>®</sup> Forte

Cytidine + Uridine Capsules

Composition:	Per capsule
<b>Active Ingredients:</b>	
Cytidine – 5'- disodium monophosphate (CMP disodium salt)	5 mg
Uridine – 5'- trisodium triphosphate (UTP trisodium salt)	
Uridine – 5'- disodium diphosphate (UDP disodium salt)	
Uridine – 5'- disodium monophosphate (UMP disodium salt)	
On the whole	3 mg
Eqv. To Uridine	1.33 mg

**Inactive Ingredients:**  
Citric acid, Sodium Citrate 2H<sub>2</sub>O, Magnesium stearate, Aerosil200, Mannitol.

**Mode of action:**

Nucleo CMP forte provides the phosphate groups necessary for the union of the monosaccharides with ceramins to form the cerebroside and phosphatidic acids constituting the sphingomyelin and glycerophospholipids, main components of the myelin sheath, thus achieving greater trophic properties for the maturation and axonal regeneration of the nervous tissue.

**Pharmacokinetics:**

The pharmaceutical product Nucleo CMP forte is an association of 2 nucleotides: CMP and UTP. These nucleotides are present in the organism. For this reason it is difficult to make a test of classic pharmacokinetics, administering product and analyzing by means of usual analytical techniques the content in biological liquids, corresponding to the external contribution.

The unique form to do is administering it noticeable product radioactively that allows to externally differentiate the organic content from the contributed one.

The tests in humans with noticeable product are questioned ethically and legally. For this reason the tests of pharmacokinetics of Nucleo CMP forte have been realized with rats to which it has administered the 2 nucleotides to them marked with C-14 carbon. The maximum plasmatic concentration, as much from CMP as UTP, is obtained to the 20 minutes of its administration by oral route. The average life oscillates between 1.5 and 5 hours, in the phase of distribution alpha. Concerning the phase of distribution beta (elimination) the average life is of 8 hours. The UTP is eliminated mainly in the form of uridine. The CMP is eliminated in one first stage as cytosine and later also doses in the form of uridine despite rest of confers its participation in metabolic processes of the organisms.

**Pharmacodynamics:**

The activity of Nucleo CMP forte is derived from the incorporation of its active principles in specific metabolic routes. Nucleo CMP forte contributes to the groups necessary phosphates for the metabolism of cerebroside and the sphingomyelin and glycerophospholipids phosphatidic acids that constitute, main components of the myelin sheath, which confers to the product of trophic properties for the maturation and axonal regeneration of the nervous weave.

The experimental tests with animal to which a neuropathy takes place to them have shown that the administration of Nucleo CMP forte exerts a preventive action and curative. After the administration, it is verified that there is an increase of density of injured nervous fiber, as well as of its diameter, that is to say, increases to its consistency and thickness. This is translated in an activation of the mechanism of axonal regeneration and an increase of the speed of the axonal flow. Consequently, the inflammation is diminished, sensitivity is increased and the mobilization of affected zone improves.

**Indications:**

For treatment of peripheral neuropathies of osteoarticular, metabolic, infectious origin and to frigore. Neuralgias.

**Dosage and duration of treatment:**

Nucleo CMP forte capsules is administered by oral route

Adults: 1 or 2 capsules 2 times daily

Children: 1 capsule 2 times daily. As prescribed by physician

**Contraindications:**

Are not known unless that there exists an allergy to any of the components.

**Adverse reactions:**

Have not been described, but if any adverse reaction attributable to the taking of the medicament appears, consult your physician or pharmacist.

**Drug interactions:**

Are not known.

**Pregnancy & Lactation:**

Its use during pregnancy is not contraindicated, however, it is recommended that the dosage pattern is established by the physician.

**Precaution & Warning :**

**Measures to be taken in case of over dosage:**

Given the scarce toxicity of the preparation, poisoning is not foreseen, even by accident.

**Package & Storage:**

Pack of 1 strip of 10 capsules & leaflet.

Store at temperature not exceed 30°C in dry place, out of reach of children.

**THIS IS A MEDICAMENT**

- Medicament is a product which affects your health, and its consumption contrary to instructions is dangerous for you.
- Follow strictly the doctor's prescription, the method of use and the instructions of the pharmacist who sold the medicament.
- The doctor and the pharmacist are experts in medicine, its benefits and risks.
- Do not by yourself interrupt the period of treatment prescribed for you.
- Do not repeat the same prescription without consulting your doctor.

Keep all medicines out of the reach of children.

**Manufactured by:**

October Pharma S.A.E. 6 October City - Egypt

Under Licence of: Ferrer Internacional, S.A. Barcelona, Spain

120102721

 **ferrer**  
Apr/2011